← Leaderboards
Richard J. Whitley
University Of Alabama At Birmingham
$15,110,969
Attributed
$15,110,969
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.4M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$101,992,921 · 16
By mechanism
U19$84,586,577 · 6
P01$16,233,105 · 4
U54$834,652 · 2
N01$250,000 · 1
M01$88,587 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- David W Kimberlin$10,865,588
- James M Markert$5,310,460
- G. Yancey Gillespie$5,456,344
- Michael J Mugavero$16,567,288
- Louis B Nabors$6,698,272
Others in their field
Top investigators on “Drug Discovery”
- David Heimbrook · Leidos Biomedical Research, Inc.$369,513,553
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ralph Parchment · Leidos Biomedical Research, Inc.$137,717,670
- Daniel Ernest Ford · Johns Hopkins University$137,014,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
Research focus
Drug DiscoveryAntiviral AgentsProgramsVirusSuccessDrug DevelopmentInfluenzaVirus DiseasesLeadCollaborationsViralVirus ReplicationResearch PersonnelBaseInfectionPropertyEnsureIn VitroClinical ResearchMonitorResistanceIn VivoAlphavirusCountry
Grant awards (68)
Pilot and Feasibility Core$81,990
U54 · FY2024 · AI · contact PI
Antiviral Drug Discovery and Development Center (AD3C)$7,500,000
U19 · FY2023 · AI · contact PI
Project 4 - Influenza - UAB$1,154,081
U19 · FY2023 · AI · contact PI
Administrative Core$361,810
U19 · FY2023 · AI · contact PI
Pilot and Feasibility Core$99,641
U54 · FY2023 · AI · contact PI
Antiviral Drug Discovery and Development Center (AD3C)$7,500,000
U19 · FY2022 · AI · contact PI
Administrative Core$937,502
U19 · FY2022 · AI · contact PI
Project 4 - Influenza - UAB$937,498
U19 · FY2022 · AI · contact PI
Antiviral Drug Discovery and Development Center (AD3C)$7,499,995
U19 · FY2021 · AI · contact PI
Project 4 - Influenza - UAB$888,530
U19 · FY2021 · AI · contact PI
Administrative Core$189,630
U19 · FY2021 · AI · contact PI
Pilot and Feasibility Core$123,661
U54 · FY2021 · AI · contact PI
Antiviral Drug Discovery and Development Center (AD3C)$7,500,000
U19 · FY2020 · AI · contact PI
Project 4 - Influenza - UAB$879,614
U19 · FY2020 · AI · contact PI
Administrative Core$210,487
U19 · FY2020 · AI · contact PI
Pilot and Feasibility Core$77,207
U54 · FY2020 · AI · contact PI
Antiviral Drug Discovery and Development Center (AD3C)$7,500,000
U19 · FY2019 · AI · contact PI
Project 4 - Influenza - UAB$775,173
U19 · FY2019 · AI · contact PI
Administrative Core$211,987
U19 · FY2019 · AI · contact PI
Pilot and Feasibility Core$30,505
U54 · FY2019 · AI · contact PI
Antiviral Drug Discovery and Development Center - Overall$7,112,904
U19 · FY2018 · AI · contact PI
Identification and characterization of novel drugs that target the Influenza$945,389
U19 · FY2018 · AI · contact PI
Administrative Core$230,940
U19 · FY2018 · AI · contact PI
Antiviral Drug Discovery and Development Center - Overall$7,293,471
U19 · FY2017 · AI · contact PI
Identification and characterization of novel drugs that target the Influenza$1,044,668
U19 · FY2017 · AI · contact PI
Administrative Core$197,720
U19 · FY2017 · AI · contact PI
Antiviral Drug Discovery and Development Center - Overall$7,623,789
U19 · FY2016 · AI · contact PI
Identification and characterization of novel drugs that target the Influenza$909,915
U19 · FY2016 · AI · contact PI
Administrative Core$171,855
U19 · FY2016 · AI · contact PI
Antiviral Drug Discovery and Development Center - Overall$6,606,164
U19 · FY2015 · AI · contact PI
Identification and characterization of novel drugs that target the Influenza$909,621
U19 · FY2015 · AI · contact PI
Administrative Core$175,223
U19 · FY2015 · AI · contact PI
Antiviral Drug Discovery and Development Center - Overall$6,270,702
U19 · FY2014 · AI · contact PI
Identification and characterization of novel drugs that target the Influenza$882,792
U19 · FY2014 · AI · contact PI
Administrative Core$165,117
U19 · FY2014 · AI · contact PI
Engineered HSV For Treatment of Malignant Glioma$1,232,894
P01 · FY2013 · CA · contact PI
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy$158,410
P01 · FY2013 · CA · contact PI
Administrative Core$82,441
P01 · FY2013 · CA · contact PI
Engineered HSV For Treatment of Malignant Glioma$1,315,610
P01 · FY2012 · CA · contact PI
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy$170,931
P01 · FY2012 · CA · contact PI
Administrative Core$95,934
P01 · FY2012 · CA · contact PI
Engineered HSV For Treatment of Malignant Glioma$1,318,625
P01 · FY2011 · CA · contact PI
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy$171,981
P01 · FY2011 · CA · contact PI
Administrative Core$98,100
P01 · FY2011 · CA · contact PI
Engineered HSV For Treatment of Malignant Glioma$1,362,628
P01 · FY2010 · CA · contact PI
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy$178,065
P01 · FY2010 · CA · contact PI
Administrative Core$101,509
P01 · FY2010 · CA · contact PI
Engineered HSV For Treatment of Malignant Glioma$1,358,565
P01 · FY2009 · CA · contact PI
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy$177,555
P01 · FY2009 · CA · contact PI
Administrative Core$101,215
P01 · FY2009 · CA · contact PI
Development of Antiviral Screens and Animal Models$421,648
U54 · FY2008 · AI · contact PI
Engineered HSV for Treatment of Malignant Gliomas$1,284,905
P01 · FY2007 · CA · contact PI
Engineered HSV for Treatment of Malignant Gliomas$1,301,266
P01 · FY2006 · CA · contact PI
Engineered HSV for Treatment of Malignant Gliomas$1,304,081
P01 · FY2005 · CA
Engineered HSV for Treatment of Malignant Gliomas$1,195,836
P01 · FY2004 · CA
Engineered HSV for Treatment of Malignant Gliomas$1,028,381
P01 · FY2003 · CA
HIGH DOSE ACYCLOVIR VERSUS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION$0
M01 · FY2002 · RR
GANCICLOVIR (DHPG) FOR SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2002 · RR
ENGINEERED HERPES SIMPLEX VIRUS FOR TREATMENT OF GLIOMAS$897,832
P01 · FY2001 · CA
BIOLOGIC CHARACTERIZATION OF ENGINEERED HSV FOR THERAPY OF BRAIN TUMORS$206,819
P01 · FY2001 · CA
HIGH DOSE ACYCLOVIR VERSUS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION$0
M01 · FY2001 · RR
GANCICLOVIR (DHPG) FOR SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2001 · RR
ENGINEERED HERPES SIMPLEX VIRUS FOR TREATMENT OF GLIOMAS$874,304
P01 · FY2000 · CA
CLINICAL STUDIES OF THERAPIES FOR VIRUS INFECTIONS$250,000
N01 · FY2000 · AI
BIOLOGIC CHARACTERIZATION OF ENGINEERED HSV FOR THERAPY OF BRAIN TUMORS$215,218
P01 · FY2000 · CA
HIGH DOSE ACYCLOVIR VERSUS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION$29,529
M01 · FY2000 · RR
PDL MSL 109 IN INFANTS WITH NON CNS SYMPTOMATIC CONGENITAL CMV INFECTIONS$29,529
M01 · FY2000 · RR
GANCICLOVIR (DHPG) FOR SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTIONS$29,529
M01 · FY2000 · RR